(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes - 2Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- 3Civilian toll mounts in Iran as war presses on
- 4Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 5Pick Your #1 game to observe
- Former biotech CEO sued over COVID vaccine alleged insider trading
- Opening Your True capacity: 12 Techniques for Personal growth
- Egypt seeks to calm tourist fears over fallout of Iran war
- Change Your Home into an Exercise center with These Famous Wellness Gadgets
- Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- Astonishing interstellar comet captured in new images by NASA Mars missions
- 21 Things You Ought to Never Share with Your Childless Companion
- China Just Got Another Cheap EV America Would Love to Have
- 'You're no longer my sister' - rows erupt as war divides Iranian families
